regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-11 and is reviewed periodically as new material appears.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
We thus come to the remarkable conclusion that, beyond doubt, Van Leeuwenhoek in his experiment with the fully closed tube had cultivated and seen genuine anaerobic bacteria, which would happen again only after 200 years, namely about 1862 by Pasteur. That Leeuwenhoek, one hundred years before the discovery of oxygen and the composition of air, was not aware of the meaning of his observations is understandable. But the fact that in the closed tube he observed an increased gas pressure caused by fermentative bacteria and, in addition, saw the bacteria, prove, in any case, that he not only was a good observer but also was able to design an experiment from which a conclusion could be drawn.
== 1944–45: The retreat == By early 1944, the 4th Panzer Army had been pushed back to the pre-war 1939 Polish border. The army defended positions in Ukraine west of Kiev until late June 1944, fighting in the southern regions of the Pinsk Marshes, and around Lutsk, Shepetovka, Tarnopol, and Kovel in western Galicia. However, following the transfer of several of its panzer divisions northwards in the aftermath of Army Group Center's collapse in Operation Bagration, 4th Army was progressively outmatched and forced into a fighting withdrawal by the 1st Ukrainian Front during the Lvov–Sandomierz Offensive. The right flank of 4th Army, including XIII Army Corps, was surrounded and destroyed at Brody in late July, 1944. By August 1944, Soviet attacks forced a full retreat of the 4th Panzer Army through the area of Chełm and Lublin, ending on the west bank of the Vistula River and an initially successful attempt to contain the Soviet bridgehead at Baranow. In November 1944, the army was composed of:
The batch-to-batch variations arising from the needs during the mentioned methodology can be overcome by utilizing technical components for mixing and growth as well as transport and temperature adjustments. For the production of CdSe based semiconductor nanoparticles this method has been investigated and tuned to production amounts of kilograms per month. Since the use of technical components allows for easy interchange in regards of maximum throughput and size, it can be further enhanced to tens or even hundreds of kilograms. In 2011 a consortium of U.S. and Dutch companies reported a milestone in high-volume quantum dot manufacturing by applying the traditional high temperature dual injection method to a flow system. On 23 January 2013 Dow entered into an exclusive licensing agreement with UK-based Nanoco for the use of their low-temperature molecular seeding method for bulk manufacture of cadmium-free quantum dots for electronic displays, and on 24 September 2014 Dow commenced work on the production facility in South Korea capable of producing sufficient quantum dots for "millions of cadmium-free televisions and other devices, such as tablets". Mass production was due to commence in mid-2015. On 24 March 2015, Dow announced a partnership deal with LG Electronics to develop the use of cadmium free quantum dots in displays.
== Investigation == Mendonça's tutor called his parents because the child had not turned up for his 5:00 PM lesson, and they quickly initiated a search for him. Because Mendonça had told his mother that he was planning to meet up with his friend Dias, the police sought him for questioning. Dias was in an emotional state while being questioned, and simply replied that he did not know the boy's whereabouts, but that the police "should close the borders". Dias was interrogated by the police. Mendonça's cousin, João André Mendonça, recounted to the police that he, Mendonça and Dias had had a conversation where Dias had invited them to go meet up with a prostitute. The cousin said he had not joined Mendonça and Dias that afternoon because his mother would not let him leave the house. The police considered the possibility of kidnapping, slavery, homicide and suicide.
Alcapurrias are a traditional snack with masa dough made from grated green banana, yautía, seasoned with lard, annatto and stuffed with picadillo. Alcaparrado de plátano have additional grated plantain added to the masa. Mofongo is a beloved dish on the island celebrating a blend of cultures making it one of Puerto Ricos most important dishes. Plantains are fried once and mashed with garlic, fat (butter, lard or olive oil), chicharrón or bacon, and broth it is then formed into a ball and eaten with other meats, soup, vegetables or alone. Puerto Rican piononos are sweet and savory treats made with a combination of fried yellow plantains, cheese, picadillo, and beaten eggs. The result is sweet plantain cups stuffed with a cheese, ground beef and fluffy egg filling. Ralleno de plátano are the sweet plantain verson of papa rellena very popular street food and in cuchifritos.
Sources: en.wikipedia.org
=== Switzerland === In Switzerland, the sale and production of absinthe was prohibited from 1910 to 1 March 2005. This was based on a vote in 1908, inspired by the Jean Lanfray incident. To be legally made or sold in Switzerland, absinthe must be distilled, must not contain certain additives, and must be either naturally coloured or left uncoloured. In 2014, the Federal Administrative Court of Switzerland invalidated a governmental decision of 2010 which allowed only absinthe made in the Val-de-Travers region to be labelled as absinthe in Switzerland. The court found that absinthe was a label for a product and was not tied to a geographic origin.
== References == Ciguatera fish poisoning, CDC Friedman, M. A.; Fernandez, M.; Backer, L. C.; Dickey, R. W.; Bernstein, J.; Schrank, K.; Kibler, S.; Stephan, W.; Gribble, M. O.; Bienfang, P.; Bowen, R. E.; Degrasse, S.; Flores Quintana, H. A.; Loeffler, C. R.; Weisman, R.; Blythe, D.; Berdalet, E.; Ayyar, R.; Clarkson-Townsend, D.; Swajian, K.; Benner, R.; Brewer, T.; Fleming, L. E. (2017). "An Updated Review of Ciguatera Fish Poisoning: Clinical, Epidemiological, Environmental, and Public Health Management". Marine Drugs. 15 (3): 72. Bibcode:2017MarDr..15...72F. doi:10.3390/md15030072. PMC 5367029. PMID 28335428.
Records of attempts at pregnancy testing have been found as far back as the ancient Greek and ancient Egyptian cultures. The ancient Egyptians watered bags of wheat and barley with the urine of a possibly pregnant woman. Germination indicated pregnancy. The type of grain that sprouted was taken as an indicator of the fetus's sex. Hippocrates suggested that a woman who had missed her period should drink a solution of honey in water at bedtime: resulting abdominal distention and cramps would indicate the presence of a pregnancy. Avicenna and many physicians after him in the Middle Ages performed uroscopy, a nonscientific method to evaluate urine. Selmar Aschheim and Bernhard Zondek introduced testing based on the presence of human chorionic gonadotropin (hCG) in 1928. Early studies of hCG had concluded that it was produced by the pituitary gland. In the 1930s, Doctor Georgeanna Jones discovered that hCG was produced not by the pituitary gland, but by the placenta. This discovery was important in relying on hCG as an early marker of pregnancy. In the Aschheim and Zondek test, an infantile female mouse was injected subcutaneously with urine of the woman to be tested, and the mouse later was killed and dissected. Presence of ovulation indicated that the urine contained hCG and meant that the subject was pregnant. A similar test was developed using immature rabbits.
==== Side effects ==== The most common side effects are nausea and vomiting, both of which are linked to cholinergic excess. These side effects arise in approximately 10–20% of users, are mild to moderate in severity, and can be managed by slowly adjusting medication doses. Less common secondary effects include muscle cramps, decreased heart rate (bradycardia), decreased appetite and weight, and increased gastric acid production. Reported adverse events with memantine are infrequent and mild, including hallucinations, confusion, dizziness, headache, and fatigue.
user error in performing and interpreting the test, biochemical pregnancy (loss of pregnancy before signs of pregnancy are apparent on ultrasound, likely very soon after implantation), non-pregnant production of the hCG molecule (i.e. secretion due to a tumor or the pituitary gland, some diseases of the liver, cancers, including choriocarcinoma and other germ cell tumors, IgA deficiencies, heterophile antibodies, enterocystoplasties, gestational trophoblastic diseases (GTD), and gestational trophoblastic neoplasms). bacterial contamination and blood in urine Spurious evaporation lines may appear on many home pregnancy tests if read after the suggested 3–5 minute window or reaction time, independent of an actual pregnancy. False positives may also appear on tests used past their expiration date.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.